Replies to post #47020 on China Growth Stocks

[Bob Stocks]

LTUS Bunky is right....this is also a big factor why i'm buying and holding. I'm not selling this for chump change.


Lotus Pharmaceuticals' Laevo-Bambuterol Received SFDA Approval to Commence Clinical Trials
Lotus Pharmaceuticals' Laevo-Bambuterol Received SFDA Approval to Commence Clinical Trials
Apr. 29, 2010 (PR Newswire) --

BEIJING, April 29 /PRNewswire-Asia-FirstCall/ -- Lotus Pharmaceuticals, Inc. (OTC Bulletin Board: LTUS) ("Lotus" or the "Company"), a growing developer, manufacturer and seller of medicine and drugs in the People's Republic of China (the "PRC") today reported that its innovative asthma drug Laevo-Bambuterol has received approval from China's State Food & Drug Administration's (SFDA) to commence clinical trials (No.2010L01309 and 2010L01399).

R-Bambuterol(R) Hydrochloride Tablets ("Laevo-Bambuterol") is categorized as a Class 1 new drug. Its preclinical studies show that it is more effective and have lower toxicity than Bambuterol, a popular asthma drug currently on the market.

The Company is communicating with experts from the SFDA's Drug Review and Evaluation Center on the designs for clinical trials and expects the new product to launch in 2013-2014.

Safe Harbor Statement